Advancing Parkinson’s Disease Research Through Smarter Clinical Trial Partnerships

How Foundations, Biotech and Pharma Organizations Can Accelerate Parkinson’s Studies with the Right Clinical Research Partner

Parkinson’s disease research is entering a pivotal era. As scientific understanding of neurodegenerative disorders expands, organizations are moving beyond symptom management toward disease modification, precision therapies, biomarkers, digital monitoring and patient-centered care models.

But with innovation comes complexity. Parkinson’s disease clinical trials are often long-term, multi-site, data-intensive and operationally demanding. Patient retention, protocol amendments, decentralized assessments, caregiver involvement and advancing endpoints can make execution challenging for even the most experienced sponsors.

For foundations, biotech companies, pharmaceutical organizations and academic research groups, selecting the right clinical development partner and accessing strong biotech clinical trial support has become critical to advancing Parkinson’s disease research faster and more effectively.

Navitas Life Sciences brings deep therapeutic expertise, operational agility and scalable clinical capabilities to support Parkinson’s disease studies from early planning through long-term execution. We are proud to collaborate with organizations driving innovation in neurology and neurodegenerative diseases and excited to announce that our team will be present at the World Parkinson Congress 2026.

 

The Growing Complexity of Parkinson’s Disease Clinical Trials

Parkinson’s disease affects more than 10 million people globally and the need for effective therapies continues to grow. Yet Parkinson’s studies remain among the most operationally complex clinical programs in the industry.

Sponsors today face challenges such as:

• Recruiting and retaining patients across long study durations
• Managing caregiver-dependent participation
• Supporting decentralized and hybrid trial models
• Integrating wearable technologies and digital biomarkers
• Leveraging real-world data (RWD) and real-world evidence (RWE) together with clinical research data to generate more comprehensive and actionable insights
• Handling expanding data volumes and longitudinal patient data
• Coordinating multiple stakeholders across sites, CROs, advocacy groups and investigators
• Ensuring consistency across global or multi-regional studies

For foundations and emerging biotech organizations especially, balancing scientific ambition with operational scalability can be difficult without the right partner ecosystem. Long-duration neurological programs require strong clinical trial operational support, regulatory compliance guidance, and multidisciplinary clinical data science expertise, along with modern technology capabilities, to ensure consistency, sustain patient engagement, and delivery data quality and actionable data insights.

That is where Navitas Life Sciences provides value.

A Strategic Partner for Parkinson’s Disease Research

Navitas Life Sciences supports organizations conducting complex neurological and Parkinson’s disease studies with integrated clinical development, site management, data and eSolution, regulatory and patient-focused solutions. As an experienced Parkinson’s disease CRO, Navitas Life Sciences supports organizations conducting complex neurological and long-term clinical studies.

Q&A with Dr Yun Lu: Supporting the Next Generation of Parkinson’s Disease Studies

To better understand the operational realities and the needs of Parkinson’s disease research, we spoke with Dr. Yun Lu, VP & Chief Science and Innovation Officer about managing long-term studies, supporting patient-centered research models, and helping foundations, biotech and pharma organizations navigate growing clinical trial complexity.

Q. Parkinson’s disease studies often take over several years with expanding research goals and patient needs. How does Navitas help organizations manage that growing complexity while maintaining operational consistency?
Long-term Parkinson’s studies require operational execution, stability, adaptability and teams that understand how research studies grow over time.

Navitas, as both the clinical operations coordinating center and clinical data coordinating center, helps organizations build scalable operational models that can evolve as the program portfolio expands. This includes supporting expanding protocols, managing increasing data complexity, coordinating multiple stakeholders and adapting to evolving scientific priorities, all while maintaining consistency for investigators, sponsors and most importantly, patients.

One of the biggest realities of Parkinson’s research is that patient journeys are long. According to the Parkinson's Foundation, nearly 10 million people worldwide are living with Parkinson’s disease, and because it is a progressive condition, long-term observational and longitudinal registry studies play a critical role in understanding disease progression, treatment outcomes and quality of life.

That creates operational pressure. Studies often continue for years. Teams change. Data volumes grow. Technologies evolve. Sub-studies are introduced. Patient retention becomes increasingly important.

This is where operational continuity matters. Our teams focus heavily on structured governance, proactive communication and flexible delivery models that allow programs to grow without losing consistency. Sometimes that means adapting workflows mid-study. Sometimes it means integrating new data collection requirements or supporting decentralized engagement approaches to reduce patient burden.

And often, it simply means being a reliable long-term partner that foundations and biotech can count on as complexity increases.

Q. What capabilities and experience does Navitas Life Sciences bring to biotech companies, foundations and research organizations conducting long-term Parkinson’s disease studies?
Parkinson’s disease research demands collaboration across science, operations, technology and patient engagement. No single capability works in isolation anymore.

We support research organizations across clinical operations, clinical data management, patient registries, biostatistics, pharmacovigilance, medical writing, regulatory support and decentralized trial enablement. But beyond the individual capabilities, what truly matters is how these functions work together to support long-term studies and programs.

Over the past 35 years, we have supported multiple programs, across therapeutic areas, that have grown significantly beyond their original scope. What started as individual studies expanded into broader research initiatives involving multiple sub-studies, larger patient populations and growing operational demands. It requires institutional knowledge.

We also recognize that foundations and biotech companies operate differently. Foundations are often deeply focused on long-term patient outcomes and community engagement, while biotech organizations may be balancing speed, innovation and changing development priorities. Supporting both effectively requires adaptability and a highly collaborative mindset.

That partnership mindset is central to how we work with various sponsors and clients.

Q. How is Navitas positioned to support the next generation of patient-centered studies and research initiatives?
The future of Parkinson’s research is becoming more connected, more data-driven and far more patient-centered than ever before.

Research organizations today are looking beyond traditional study models. There is growing interest in master study design, patient-centric decentralized and hybrid approaches, wearable technologies, real-world evidence generation, digital biomarkers and continuous patient engagement strategies that allow researchers to better understand disease progression in real-life settings.

Navitas is continuing to advance our operational and technology capabilities to support this next generation of research. We help organizations build scalable study frameworks that can support evolving endpoints, remote participation models, expanding clinical and RWD/RWE datasets, and long-term patient follow-up requirements.

Proven Experience Supporting Long-Term Parkinson’s Disease Research

Building on more than five years of collaboration supporting Parkinson’s disease research initiatives with the Parkinsons Foundation, Navitas Life Sciences brings the operational experience, therapeutic understanding, clinical data science expertise and scalable infrastructure needed to support complex long-term studies across foundations, biotech companies and pharmaceutical organizations.

 

In the following conversation, Sarah Lawrence, Associate Director, CDO, shares insights into Parkinson’s disease research and what organizations should look for in a long-term clinical research partner. Navitas continues to serve as a strategic Parkinson’s disease research partner for The Parkinsons Foundation, and here are insights from the support.

Q. What does a successful partnership in clinical research look like beyond just meeting milestones?
Successful partnerships in clinical research occur when there is mutual understanding of the value that each partner brings to a program. When sponsors know when to bring in expert partners to guide them in areas where they may have less expertise, it establishes a foundation of trust in one another’s capabilities. In return, clients should seek feedback and input from their sponsors on an ongoing basis to ensure they have a full grasp on how exactly to apply their skillset in a way that is useful and meaningful. Establishing this level of confidence in each other’s knowledge and skillset is essential to grow and sustain successful clinical research programs.

Q. What drove the decision to introduce sub-studies over time?
Clinical registries that offer high-quality, meaningful data to stakeholders become self-sustaining. The success of these registries is driven by the value they offer to populations that are impacted by a disease or condition and the clinicians that treat them, and these data repositories become an essential commodity in these communities. These types of self-sustaining registries naturally invite the development of sub-studies that will enhance the value of the existing data and further define a specific cohort of individuals in the study. Stakeholders understand the potential that sub-studies offer and it becomes impossible not to take advantage of the opportunity to learn more and drive further research towards knowledge, effective treatments, and cures.

Q. How did Navitas get included into supporting sub-studies?
As a CRO with extensive experience supporting registry studies, the partnership with the Parkinson’s Foundation to support PD GENEration developed significantly over the years. As our teams continued to work together to grow the registry and worked to evolve workflows to support stakeholder needs, the partnership naturally evolved as the demand for substudies to further define specific populations in PDGENE grew. With expertise in regulatory, clinical operations, and data management, Navitas is able to support the expansion of PDGENE into substudies and our team continues to collaborate extensively with the scientists, disease experts, and patient representatives within the Foundation.

Q. How did operational flexibility help accommodate the growing complexity of the program?
Over the course of patient enrollment to PDGENE, the Parkinson’s Foundation worked closely with stakeholders to support mission-driven science and data quality. As the goals for the registry evolved, it was critical for PF and Navitas to sustain the core processes that made PDGENE successful, while also adapting to the registry’s growth and expansion. Working in partnership, our teams spent significant time strategizing on how to maintain core operations while also adding in necessary enhancements for scalability. Having an open mind to technology, understanding how to navigate regulatory guidelines, and consistently building in checkpoints and opportunities for data quality control are necessary procedures to scale for growth in expanding registry studies.

Meet Navitas Life Sciences at the World Parkinson Congress 2026

We are excited to share that Navitas Life Sciences will be present at the World Parkinson Congress 2026, where global leaders, researchers, clinicians, foundations and innovators will come together to shape the future of Parkinson’s disease care and research.

The congress represents an important opportunity to discuss:

• Emerging Parkinson’s disease research trends
• Clinical trial innovation
• Patient-centered study models
• Real-world evidence strategies
• Long-term registry management
• Scalable operational partnerships for neurology programs

We look forward to connecting with organizations working to advance Parkinson’s disease research and improve patient outcomes worldwide.

Partnering to Accelerate Parkinson’s Disease Research

Advancing Parkinson’s disease therapies requires more than scientific innovation alone. It requires operational resilience, therapeutic expertise, patient-focused execution, and trusted collaboration.

Navitas Life Sciences help foundations, biotech companies, pharmaceutical organizations and research institutions support Parkinson’s disease clinical development with confidence.

Whether supporting long-term registries, complex global studies, decentralized trials or emerging therapeutic programs, our teams are committed to helping organizations move research forward.

Connect with our team at the World Parkinson Congress 2026 to learn how Navitas Life Sciences can support your Parkinson’s disease research and clinical development goals.

Learn more about our services and solutions by reaching out to us at This email address is being protected from spambots. You need JavaScript enabled to view it..